The Renal Risk in Derby (RRID) Study is a prospective cohort study of people with CKD stage 3 in primary care. Recruitment began in June 2008 and completed in April 2010. Year-5 follow-up visits were completed in April 2015.
Chronic kidney disease affects 10-20% of adults in most countries and is associated with multiple adverse outcomes including increased risk of death, progression to end-stage kidney disease (requiring dialysis or kidney transplantation) and increased risk of diseases of the heart and arteries
The risk of these adverse outcomes varies considerably and previous studies indicate that most people with chronic kidney disease are at low risk.
Many previous studies have been conducted in large teaching hospitals and have understandably emphasized the risk of end-stage kidney disease but the results may not be applicable to the majority with chronic kidney disease because most have mild disease, are cared for by family doctors and are never referred to a kidney specialist.
We started the RRID study to better understand the risks associated with chronic kidney disease in people cared for by family doctors in order to provide a perspective that is applicable to the majority of people affected.
We plan to investigate the role of a range of common clinical variables and novel factors (including skin autoflourescence, pulse wave velocity and cystatin C) in determining risk for individuals with CKD stage 3 in primary care.
The RRID study is currently funded by a research grant from the Dunhill Medical Trust.
Previous phases of the study were funded by a Fellowship award from Kidney Research UK and the British Renal Society as well as grants from Roche Products PLC and a research grant from Genzyme, now a part of Sanofi.
No Pharmaceutical company had any role in the design or conduct of the study. The results are wholly owned by the investigators.
We have published a range of journal articles from data collected from the RRID study. Additionally, many results have been presented at national and international conferences. Journal articles published are listed below.
|Arterial stiffness||Stiffness of the wall of the arteries in the body. Greater arterial stiffness is associated with a higher risk of heart disease.|
|CKD||Chronic kidney disease. A condition that causes kidney function to be lower than normal for at least 3 months. There are many different causes of CKD. The term “chronic” does not mean severe; it means simply that the condition has existed for 3 months or more.|
|Creatinine||A chemical in the blood that is normally cleared by the kidneys. Higher levels of creatinine are seen when kidney function is lower than normal.|
|Cystatin C||A chemical in the blood that is normally cleared by the kidneys. Higher levels of cystatin C are seen when kidney function is lower than normal.|
|Primary Care||Healthcare delivered by GP practices.|
A study in which people are evaluated at the start and are then monitored over a period of time.
|Pulse wave velocity||The speed at which a pressure wave travels along the arteries each time the heart beats. Higher pulse wave velocity is associated with stiffer arteries and stiff arteries are associated with a higher risk of heart disease.|
|Retrospective Study||A study in which people are evaluated at a point in time and their current condition is compared to their condition at some point in the past.|
Healthcare delivered by hospitals.
A measurement of light that reflects off the skin when exposed to ultraviolet light. This is a measure of the accumulation in the skin of chemicals called advanced glycation end-products (AGEs). Higher SAF has been associated with a higher risk of heart disease and death in some studies.